Schwab U.S. Dividend Equity ETF (SCHD) Gains $679M Amid Strong Performance
The Schwab U.S. Dividend Equity ETF (SCHD) attracted over $679 million in inflows as its share price rose by 2.39% across five trading days, driven largely by strong performances from key holdings like Merck and Abbott. The fund's March reconstitution reshaped its portfolio, adding major names such as UnitedHealth Group and Procter & Gamble while reducing energy exposure. Merck saw a significant boost after positive results in an mRNA cancer vaccine trial with Moderna, prompting upgrades from top banks including Morgan Stanley and UBS. Abbott also benefited from litigation settlements related to infant formula issues. Amgen advanced its clinical trials for new drug formulations during the same period. The fund's performance has outpaced broader market indices this year by nearly 18 percentage points, reversing a multi-year trend of underperformance. The Federal Reserve’s pause on rate hikes appears to have supported continued inflows into dividend-focused funds like SCHD.
Tickers: $ABT $AMGN $MRK $MRNA $PG $SCHD $SCHW $UNH
Topics: clinical trials dividends ETF pharmaceuticals stock performance